<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993394</url>
  </required_header>
  <id_info>
    <org_study_id>10co706</org_study_id>
    <nct_id>NCT01993394</nct_id>
  </id_info>
  <brief_title>Effect of Hyperoxia and Hypergravity on Lung Ventilation and Perfusion</brief_title>
  <official_title>Influence of Hyperoxia and Hypergravity on Pulmonary Ventilation and Perfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direction Centrale du Service de Santé des Armées</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Val de Grâce Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Direction Centrale du Service de Santé des Armées</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this project is to get further knowledge on the effects of + Gz
      accelerations and hyperoxia on lung ventilation in humans. The secondary aim is to study lung
      perfusion and cardiovascular function in these conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experiments were conducted in a human centrifuge. The protocol aimed at mimicking a routine
      peacetime flight in combat aircraft, and included 10-min exposure to +1.4 - +3.5 Gz. Subjects
      were exposed three times to this sequence, breathing air, 44.5% O2 or 100% O2.

      Ten volunteers wearing anti-G trousers participated in the study. The Ethics Committee
      Ile-de-France III and the French National Agency for Drug Safety (ANSM) approved the protocol
      (number 2009-A01092-55).

      Three different imaging techniques, electrical impedance tomography (EIT), pulmonary
      ultrasound and chest SPECT/CT were used and compared. EIT enabled ventilation monitoring in
      the human centrifuge, whereas pulmonary ultrasound and SPECT/CT gave functional and
      topographical information before and after exposure to +Gz accelerations. EIT analysis
      focused on regional ventilation, SPECT on global lung ventilation and perfusion, CT on the
      presence of atelectasis, and pulmonary ultrasound analysis looked for comet tails in 64 chest
      areas. Arterial blood pressure was recorded continuously by finger photoplethysmography.
      Cardiac output and stroke volume were computed from these recordings, using three different
      algorithms. Echocardiography was used as reference non-invasive technique for stroke volume
      determination and performed before and after exposure to +Gz accelerations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in regional ventilation distribution</measure>
    <time_frame>baseline, 2hrs 30min</time_frame>
    <description>&quot;per lobe and per quadrant at 5th intercostal space level&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in regional pulmonary perfusion</measure>
    <time_frame>baseline, 2hrs 30min</time_frame>
    <description>&quot;per lobe and per quadrant at 5th intercostal space level&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac output (L/min)</measure>
    <time_frame>2hrs</time_frame>
    <description>&quot;echocardiography (sub-aortic diameter), photoplethysmography (Liljestrand, systolic area and Windkessel algorithms)&quot;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>tidal volume</measure>
    <time_frame>2hrs 30min</time_frame>
    <description>global (mL, area under the flow versus time curve) and regional (% change per quadrant at 5th intercostal space level)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Atelectasis</condition>
  <arm_group>
    <arm_group_label>ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypergravity gas mixture</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hypergravity</intervention_name>
    <description>1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)</description>
    <arm_group_label>ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>gas mixture</intervention_name>
    <description>breathing air, 44.5%O2 or 100%O2</description>
    <arm_group_label>ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal lung function checked by pulmonary function tests

        Part 1 exclusion Criteria:

          -  past medical history of heart or lung disease

          -  current medical treatment for heart or lung disease

          -  smoking

          -  bad tolerance to +Gz accelerations (G-induced loss of consciousness, motion sickness)

        Part 2 exclusion criteria:

          -  past medical history of heart or lung disease

          -  current medical treatment for heart or lung disease

          -  smoking

          -  The use of medication for hypertension

          -  asymmetric values of left/right humeral arterial blood pressure

          -  significant echocardiographic abnormalities or bad echogenicity

          -  bad tolerance to +Gz accelerations (G-induced loss of consciousness, motion sickness)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Garin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Armed Forces Biomedical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Armed Forces Biomedical Research Institute</name>
      <address>
        <city>Brétigny-sur-Orge</city>
        <zip>91 223</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Val-de-Grâce hospital</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Direction Centrale du Service de Santé des Armées</investigator_affiliation>
    <investigator_full_name>Stéphanie Montmerle-Borgdorff</investigator_full_name>
    <investigator_title>researcher</investigator_title>
  </responsible_party>
  <keyword>human centrifuge, oxygen, imaging, stroke volume, lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Atelectasis</mesh_term>
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

